UNSPSC 51384506: Dexketoprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6KD9E78X68, chemically known as hydratropic acid, m-benzoyl-, (+)- but generally known as dexketoprofen, which bears US NIH Compound Identifier 667550. European Medicines Agency schedules Dexketoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07034MIG.

UNSPSC 51384506 Dexketoprofen is a Commodity code capturing pharmaceutical products that state and local health agencies and cooperative purchasing groups procure as part of community health, pharmacy benefit, and emergency response initiatives. While the code's nominal scope is a single anti-inflammatory medication, recent state and local solicitations under this tag show a broader pattern: counties and state health agencies are buying emergency response drugs (naloxone), multi-source generic pharmaceuticals through cooperative purchasing agreements, and exploring direct-to-manufacturer prescription models to manage pharmacy costs and supply chain efficiency. The issuing bodies span county health departments, state health commissions, and multistate cooperative purchasing alliances serving multiple jurisdictions and participating agencies.

Activity appears concentrated in Florida and Minnesota-led cooperative purchasing, with Texas state health commission market research. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to its community health building and a due date of July 26, 2023 (note: date inconsistency in source). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers and contract effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. These solicitations indicate state and local emphasis on cost control, supply chain transparency, and emergency preparedness rather than individual drug procurement.